Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 20;2(1):e000021. doi: 10.1136/bmjgast-2014-000021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Short-term and long-term outcomes of the 29 patients with severe ulcerative colitis (UC). Short-term outcomes: 14 of 22 patients in the tacrolimus (TAC) group and 5 of 7 patients in the infliximab (IFX) group achieved a clinical remission (CR) at 8 weeks after initiating TAC or IFX. Two patients in the TAC group were refractory to TAC and required sequential therapy. Two patients in the IFX group were refractory to IFX and one could achieve a CR after switching to TAC. The remaining one resulted in colectomy without switching to TAC. The CR rate at 8 weeks in the TAC and IFX groups was 63.6% and 71.4%, respectively. Long-term outcomes: In the TAC group, of 14 patients who achieved a CR at 8 weeks after initiating TAC, 11 patients could maintain a CR and 3 flared-up. A total of nine patients could not achieve and maintain a CR with TAC. Six of the nine patients could achieve a CR by sequential therapy, and the remaining three resulted in colectomy (one patient within 6 months). Two patients who required sequential therapy within 8 weeks after initiating TAC resulted in colectomy within 6 months after initiating TAC. In the IFX group, of four patients who achieved a CR at 8 weeks after initiating IFX, three could maintain a CR and one flared-up. A total of two patients could not achieve and maintain a CR with IFX and they could achieve a CR by sequential therapy. One patient who achieved a CR by sequential therapy within 8 weeks after initiating IFX could maintain a CR. *Reveals the patient who resulted in colectomy within 6 months after initiating TAC or IFX.